Partnerships & Mergers

The agreement brings together BoomRay’s expertise in radioligand therapy development and Novartis’ global capabilities in radiopharmaceutical research and commercialisation.

The collaboration will assess selected targets for several therapeutic approaches, including antibody-drug conjugates (ADCs), multispecific antibodies and T cell engagers (TcEs).

The agreement covers licensing, development, manufacturing and commercialisation of the candidate, which is currently in the early stages of development.

The arrangement gives Ona Therapeutics access to WuXi XDC’s capabilities across ADC development and manufacturing as it advances the candidate towards clinical development.

Under the new agreement, Ori will work with its partner to modernise the manufacturing process for an autologous cell therapy.

QurCan will focus on developing and optimising genetic therapeutics using its delivery technology, while Lilly will take responsibility for advancing selected candidates through subsequent development stages.

It builds on an earlier MoU signed by the two organisations in 2022 and sets out areas for deeper collaboration on health system strengthening and emerging health challenges.

The agreement establishes a framework for joint action against Bundibugyo virus disease, viral haemorrhagic fevers, cholera and other infectious disease threats that could spread across the border.

Exegenesis Bio designed EMC181 to improve the delivery of genetic medicines to muscle tissue while limiting exposure to the liver.

The approach is intended to support drug discovery in neurology, where diseases often arise from complex interactions involving genetic, developmental, neural network, immune and environmental factors.